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Spinal muscular atrophy (SMA) is a lethal human
disease characterized by motor neuron dysfunction
and muscle deterioration due to depletion of the
ubiquitous survival motor neuron (SMN) protein.
Drosophila SMN mutants have reduced muscle size
and defective locomotion, motor rhythm, and motor
neuron neurotransmission. Unexpectedly, restora-
tion of SMN in either muscles or motor neurons did
not alter these phenotypes. Instead, SMN must be
expressed in proprioceptive neurons and interneu-
rons in the motor circuit to nonautonomously correct
defects in motor neurons and muscles. SMN deple-
tion disrupts the motor system subsequent to circuit
development and can be mimicked by the inhibition
of motor network function. Furthermore, increasing
motor circuit excitability by genetic or pharmacolog-
ical inhibition of K+ channels can correct SMN-
dependent phenotypes. These results establish
sensory-motor circuit dysfunction as the origin of
motor system deficits in this SMAmodel and suggest
that enhancement of motor neural network activity
could ameliorate the disease.
INTRODUCTION
Animal behaviors such as locomotion depend upon the coordi-
nated activity of neuronal networks. Disruption of individual
components of neural circuits by injury or disease can produce
a cascade of deleterious secondary effects upon other net-
worked neurons. It has been hypothesized that the chronic
dysfunction of neuronal circuits may ultimately lead to degener-
ation of neurons within the network, both exacerbating the
damage and masking the primary cause of the disorder (Palop
and Mucke, 2010). Identifying the molecular, cellular, and phys-
iological basis of disease is central to understanding the adult
motor neuron disorder amyotrophic lateral sclerosis (ALS) (Roth-
stein, 2009) and the juvenile disease spinal muscular atrophy
(SMA) (Burghes and Beattie, 2009). The genetics of ALS are
complex, and only a minority of cases are due to the inheritanceof mutations in a diverse range of genes. By contrast, SMA, the
most common inherited cause of infant mortality (Pearn, 1978), is
both recessive and monogenic. Both ALS and SMA are charac-
terized by motor neuron functional alterations and degeneration,
which has focused research on cell-autonomous changes in
motor neurons themselves. However, recent studies of ALS
mouse models have identified contributions of other spinal
cord cells such as astrocytes to disease pathology, suggesting
that interactions between motor neurons and other partner cells
may be an important contributing factor to motor neuron disease
(Ilieva et al., 2009).
SMA is caused by recessive mutations in the survival motor
neuron 1 (SMN1) gene (Lefebvre et al., 1995) that are not
compensated for by SMN2, a human-specific gene (Burghes
and Beattie, 2009). Although SMN2 is almost identical to
SMN1, nucleotide differences alter its splicing pattern, resulting
in an 90% reduction of full-length SMN messenger RNA
(mRNA) expression (Lorson et al., 1999; Monani et al., 1999).
Therefore, SMA is caused by low levels of SMN as opposed to
the complete loss of SMN (Burghes and Beattie, 2009). SMN
is a multifunctional protein that has been implicated in a variety
of cellular processes linked to RNA metabolism (Pellizzoni,
2007). SMN is ubiquitously expressed and has been highly
conserved during evolution (Schmid and DiDonato, 2007). In
genetic model organisms, complete removal of SMN results in
loss of cell viability. In contrast, the reduced level of SMN found
in SMA patients does not appear to significantly perturb the
majority of organ systems (Crawford and Pardo, 1996). However,
SMA patients develop motor problems and muscle weakness—
with the proximal limb and trunk muscles stereotypically
being the most severely affected—progressing eventually to
respiratory insufficiency and death (Swoboda et al., 2005). Post-
mortem studies show that SMA patients have pathologically
abnormal motor neurons and evidence of motor neuron loss
(Simic, 2008); however, it is currently unclear whether this is
the primary origin of motor system dysfunction or a terminal
consequence.
Reduction of SMN to low levels—similar to the situation in
human SMA—has been studied using several animal models
(Schmid and DiDonato, 2007). In the SMA mouse model SMN-
D7, death occurs 2 weeks after birth (Le et al., 2005). This is
accompanied by a modest loss of motor neurons; however,
these mice have a profound early impairment of motor behaviorCell 151, 427–439, October 12, 2012 ª2012 Elsevier Inc. 427
well before this loss occurs (Park et al., 2010a). Examination of
the neuromuscular junctions (NMJ) of SMN-D7 mice reveals
that most terminals are innervated, though some have structural
abnormalities (Kariya et al., 2008; Kong et al., 2009; Ling et al.,
2012; McGovern et al., 2008). NMJ neurotransmission is aber-
rant in thesemutants, with an50% reduction in quantal content
(Kariya et al., 2008; Kong et al., 2009); however, the high safety
factor of the neuromuscular junction means that these terminals
still produce normal muscle twitch tension (Ling et al., 2010).
Therefore, given the early severe defects observed in the motor
behavior of SMAmice, the disruption of motor neuron function is
surprisingly modest.
SMNmutant mice have been used to grossly assess the tissue
requirements for SMN by both selective SMN rescue and deple-
tion experiments. Expression of transgenic SMN throughout the
nervous system and some muscles (Gavrilina et al., 2008) or
through central nervous system (CNS) virus delivery (Passini
et al., 2010) gives a robust rescue of SMN-D7 motor behavior
and survival, whereas muscle-specific SMN expression does
not (Gavrilina et al., 2008). In contrast, selective genetic reduc-
tion of SMN in the motor neurons of mice is not lethal, though
NMJ structural and electrophysiological abnormalities are
observed (Park et al., 2010b), and genetic restoration of SMN
in motor neurons alone does not rescue mutant lethality (Go-
gliotti et al., 2012; Martinez et al., 2012). In addition to the motor
neuron defects, pronounced early deficits of spinal reflexes and
reduced numbers of proprioceptive synaptic inputs onto motor
neurons have recently been described in SMN-D7 mice,
although functional contribution of these changes to the SMA
phenotype is not yet known (Ling et al., 2010; Mentis et al.,
2011). Collectively, these findings suggest the possibility that
neurons other than motor neurons could contribute to the motor
deficits in SMA.
Here, we have exploited Drosophilamutants with low levels of
SMN to determine the essential cellular site and requirement for
SMN in the motor system of this model. Using previously
described loss-of-function smn mutants (Chan et al., 2003;
Chang et al., 2008; Rajendra et al., 2007), we confirmed that
depletion of SMN inDrosophila results in reducedmuscle growth
and defective locomotion similar to SMA phenotypes and
showed that this was accompanied by aberrant rhythmic motor
output and neuromuscular junction neurotransmission. Surpris-
ingly, we found that none of these defects could be rescued by
transgenic restoration of SMN in either the muscles or motor
neurons of Drosophila smn mutants. Rather, we discovered
that SMN must be restored in both proprioceptive neurons and
cholinergic interneurons in order to rescue smn mutant pheno-
types. Our results reveal that the disruption of motor neurons
and muscles is a secondary consequence of a primary dysfunc-
tion of sensory-motor network activity in this SMAmodel, andwe
demonstrate that genetic or pharmacological strategies that
increase motor circuit excitability can positively benefit smn
mutant phenotypes. Furthermore, in a companion manuscript
(Lotti et al., 2012 [this issue of Cell]), we demonstrate that an
SMN-dependent gene required for normal motor circuit function
in Drosophila is also disrupted in the motor circuits of SMN
mutant mice. These results suggest that disruption of motor
circuit function may be critical to SMA and that strategies de-428 Cell 151, 427–439, October 12, 2012 ª2012 Elsevier Inc.signed tomanipulate the activity of motor networksmight be em-
ployed to ameliorate SMA patient symptoms.
RESULTS
Drosophila smnMutants HaveMuscle andMotor System
Defects
To model the low level of SMN found in SMA patients in
Drosophila, we utilized the zygotic protein null smn allele,
smnX7, which is a small deficiency that removes the entire smn
coding region without disrupting nearby loci (Chang et al.,
2008). The remaining SMN in these animals is contributed by
maternal protein, which provided <6% of the level of SMN
compared to controls at the third instar larval stage (Figure S1A
available online). smnX7 mutants never initiated pupation but
instead persisted as third instar larvae, often surviving several
days at this stage, which is consistent with other smn mutant
alleles (Chan et al., 2003). To confirm that this phenotype was
dependent on SMN, we ubiquitously expressed a transgenic
upstream activation sequence (UAS) flag-tagged SMN construct
(Chang et al., 2008) in smnX7 mutants using Actin-Gal4. This
restored normal pupation of smnX7 mutants, with 100% of larvae
initiating pupation and >80% subsequently eclose to produce
adults (data not shown). Thus, smnX7 mutants have low levels
of SMN at late larval stages and can be rescued by transgenic
SMN. We used this mutant allele for all subsequent experiments
except where noted.
In humans, depletion of SMN affects both muscles and motor
function. We noted that Drosophila smn mutant larvae were
smaller than control animals and examined whether this was
associated with a reduction in muscle size. We labeled smn
mutant and control larval muscles with phalloidin and found
that smn mutants had a 46% (p < 0.001) reduction in muscle
surface area compared to controls (Figures 1A–1C and Table
S1). This defect was fully rescued by ubiquitous expression of
transgenic SMN. smn mutant larvae were also sluggish and
moved less frequently than controls. To quantify this defect,
we used video capture and tracing software to measure their
locomotion. We found that smn mutants showed a 63% (p <
0.001) decrease in locomotion velocity compared to control
animals, which was restored to control levels by ubiquitous
expression of transgenic SMN (Figures 1D–1F). Thus, similar to
SMA patients, Drosophila larvae with low levels of SMN have
muscle and locomotion defects.
Locomotion of Drosophila larvae has been linked to the
rhythmic activity of segmental central pattern-generating net-
works (CPGs) in the ventral nerve cord (VNC) (Fox et al., 2006),
which receive inputs from both the brain hemispheres (Cattaert
and Birman, 2001) and proprioceptive sensory neurons (Cheng
et al., 2010; Hughes and Thomas, 2007; Song et al., 2007) and
output activity to motor neurons. To measure the activity of
these pattern-generating neurons, we recorded the spontaneous
activity of motor neurons in preparations where we left the brain
and VNC in situ (Fox et al., 2006). In control animals, we observed
periodic bursting of motor activity at regular intervals, which was
consistent with previous studies (Cattaert and Birman, 2001; Fox
et al., 2006) (Figure 1G). In contrast, this activity was disrupted in
smn mutants, which had short, irregular bursts that varied in
Figure 1. smn Mutants Have Reduced
Muscle Size, Decreased Locomotion,
Defective Motor Rhythm, and Aberrant
NMJ Neurotransmitter Release
(A–C) Sample images of muscles from segment A3
of control (A) and smnX7 mutant (B) third instar
larvae labeled with TRITC-phalloidin show a
reduction of muscle surface area (C) that is fully
rescued by ubiquitous expression of UAS-flag-
SMN driven by Da-Gal4 (genotype: Da-Gal4/
UAS::flagSMN; smnX7/smnX7).
(D–F) Ten sample superimposed 60 s larval loco-
motion path traces from control (D) and smnX7
mutants (E). smn mutant larvae have reduced
velocity compared to controls that was corrected
by ubiquitous expression of transgenic SMN (F).
(G–I) Recordings from muscle 6 in segment A1 of
semi-intact larval preparations where the brain,
ventral nerve cord, and motor neurons are intact.
Control larvae produce a regular motor rhythm
with periodic bursting activity corresponding to
peristaltic muscle contractions (G). smn mutant
larvae have an irregular motor pattern with short
and uncoordinated bursts as shown by an
increase in the average interspike interval (I) that is
rescued by ubiquitous expression of SMN.
(J–L) Representative traces recorded from muscle
6 of segment A3 in control (J) and smnX7mutant (K)
larvae. smnX7 mutants have increased eEPSP
amplitude as compared to controls (K). This is
corrected by ubiquitous expression of SMN (L).
Data are represented as mean ±SEM; **p < 0.01
and ***p < 0.001. See also Figure S1 and Table S1.duration (Figure 1H). We quantified this defect by measuring
the average interspike interval between all spontaneous spike
events in smn mutants and controls over a fixed time period.
Compared to controls, smn mutants showed a 90% (p < 0.001)
increase of interspike interval (Figure 1I). As with locomotion,
normal rhythmic motor activity was fully restored by ubiquitous
expression of transgenic SMN. Thus, the output of motor circuits
is defective in Drosophila smnmutants.Cell 151, 427–439,To investigate the neurotransmitter
release properties of individual motor
neurons, we removed the brain and stim-
ulated motor neurons directly by using
a suction electrode (Imlach and McCabe,
2009). Compared to controls, we found
a 23% (p < 0.005) increase of evoked
excitatory postsynaptic potential (eEPSP)
amplitude at the NMJs of smn mutants
(Figures 1J–1L). The increase of NMJ
eEPSP amplitude in smnX7 mutants was
restored to control levels by ubiquitous
expression of transgenic SMN (Figure 1L).
We also observed a 60% (p < 0.05)
increase in miniature excitatory post-
synaptic potential (mEPSP) frequency.
In contrast, mEPSP amplitude at smn
mutant NMJ terminals was not differentthan controls (Figures S2A and S2B), leading to a 64% (p <
0.001) increase in quantal content (Figure S2C). These findings
are consistent with a presynaptic change in the neurotransmitter
release properties of motor neurons in smnmutants. As our elec-
trophysiology results differed from a previous report (Chan et al.,
2003), we also examined transheterozygous combinations of
smnX7 with other smn mutant alleles and confirmed similar
changes in eEPSP amplitudes in these mutants that were notOctober 12, 2012 ª2012 Elsevier Inc. 429
Figure 2. SMN Expression Is Required in Neurons, but Not in Muscles, to Rescue smn Mutants
(A–D) Sample images of muscles from segment A3 of control (A), smnX7 mutant (B), smnX7 mutants with transgenic SMN expression only in muscles (G14-Gal4/
UAS::flagSMN; smnX7/ smnX7) (C), or neurons (nsyb-Gal4/UAS::flagSMN; smnX7/smnX7) (D). Restoration of SMN expression in muscles has no effect on muscle
size; however, restoration in neurons fully rescues muscle surface area. Scale bar, 50 mm.
(E–H) Quantification of muscle surface area (E), locomotion (F), motor rhythm (G), and NMJ eEPSP amplitude (H) normalized to controls. Expression of transgenic
SMN in neurons rescues all of smn mutant phenotypes, whereas expression in muscles does not.
Data are represented as mean ±SEM; **p < 0.01 and ***p < 0.001. See also Figure S2.found in heterozygous smnX7 animals (Figure S2D). When we
examined the morphological features of smnX7 mutant NMJs,
we observed no significant difference in the number of synaptic
boutons compared to controls (Figure S2E). In summary, we find
that Drosophila smn mutants have increased NMJ-evoked
neurotransmitter release that is accompanied by defects in
muscle growth, locomotion, and motor rhythm.
Restoration of SMN in the Nervous System Rescues
smn Mutant Phenotypes
In order to identify the cell-autonomous requirement for normal
SMN levels, we used iteratively more tissue-restricted Gal4
drivers to assess rescue of smnmutants. We began by express-
ing transgenic SMN only in the muscles of smnX7 mutants using
G14-Gal4, a larval muscle-specific driver. This produced no
significant increase in muscle surface area (Figures 2C and 2E)
or effects upon the locomotion, rhythmic motor output, and
NMJ eEPSP amplitude of smn mutants (Figures 2F–2H). We
therefore tested SMN restoration only in the nervous system of
smn mutants using the neuron-specific nsyb-Gal4 driver. In
contrast to muscle restoration of SMN, panneuronal restoration
of SMN fully rescued the muscle surface area of smnmutants to
control levels (Figures 2B, 2D, and 2E) and also completely
restored their locomotor velocity, rhythmic motor output, and
NMJ eEPSP amplitudes (Figures 2F–2H). Neuron-only rescue430 Cell 151, 427–439, October 12, 2012 ª2012 Elsevier Inc.of smn mutants was not sufficient to produce viable Drosophila
adults (data not shown), presumably due to the SMN level in
tissues that are not rescued, becoming depleted to the point
where cellular viability was compromised. Our results estab-
lished that the defects of muscle growth in smn mutant larvae
are due to a nonautonomous requirement for normal SMN levels
in the nervous system rather than in muscle fibers themselves.
SMN Is Required in Cholinergic Neurons and Not
in Motor Neurons
The Drosophila VNC, like the human spinal cord, is populated by
neurons with diverse neurotransmitter expression. AllDrosophila
motor neurons, in addition to a subset of central interneurons,
are glutamatergic (Daniels et al., 2008). Because we observed
presynaptic defects in neurotransmitter release at the NMJ in
smn mutants, we first tested the ability of transgenic SMN
expression in motor neurons to rescue smn mutants. We used
OK371-Gal4, an enhancer trap inserted in the vesicular gluta-
mate transporter promoter, to express transgenic SMN only in
the glutamatergic neurons of smn mutants. This produced no
difference in muscle surface area, locomotion velocity, or
rhythmic motor output compared to smnmutants alone (Figures
3E–3G). Surprisingly, we also observed no reduction of the aber-
rant increase of eEPSP amplitude at the NMJs of these animals
(Figures 3B, 3C, and 3H). We confirmed this unexpected result
Figure 3. SMN Expression Is Required in Cholinergic Neurons and Not in Motor Neurons
(A–D) Representative traces of control (A), smnX7 mutant (B), transgenic SMN expressed in the motor neurons of smn mutants (OK371-Gal4/UAS::SMN;
smnX7/smnX7) (C), and transgenic SMN expressed in the cholinergic neurons of smnmutants (Cha-Gal4/UAS::SMN; smnX7/smnX7) (D). Expression of transgenic
SMN in motor neurons does not restore NMJ eEPSP amplitudes in smn mutants; however, expression of SMN in cholinergic neurons does.
(E and F) Quantification of muscle surface area (E), locomotion (F), motor rhythm (G), and NMJ eEPSP amplitude (H) normalized to controls. Expression of
transgenic SMN in the motor neurons of smnmutants with OK371-Gal4 or OK6-Gal4 or in GABAergic neurons with GAD1-Gal4 does not rescue any phenotype.
Expression of transgenic SMN in cholinergic neurons rescues all phenotypes.
Data are represented as mean ±SEM; *p < 0.05, **p < 0.01, and ***p < 0.001. Significance was calculated versus controls.
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Figure 4. SMN Is Required in Both Proprioceptive and Central Cholinergic Neurons
(A) Expression pattern of cholinergic neuron Gal4 lines (dark green). Cha-Gal4 is expressed in both central and sensory cholinergic neurons. Clh201-Gal4 is only
expressed in md and es sensory neurons. 1003.3-Gal4, ppk-Gal4, and NP2225-Gal4 are expressed in subsets of md, es, or ch sensory neurons. Bright green
indicates the ability to rescue smn mutant phenotypes.
(B and C) UAS::CD8-GFP labeling the axons of bd and type I md sensory neurons with NP2225-Gal4 in the ventral nerve cord of wild-type (B) or smnX7 mutants
(C). Sensory axons project normally into the CNS in smn mutants. Scale bar, 10 mm.
(D–G) Quantification of muscle surface area (D), locomotion (E), motor rhythm (F), and NMJ eEPSP amplitude (G) normalized to controls (genotype: Gal4/
UAS::flagSMN; smnX7/smnX7). Expression of transgenic SMN in both central and sensory cholinergic neurons in smn mutants with Cha-Gal4 fully rescuing all
phenotypes. Restoration of SMN in all sensory neurons or only proprioceptive type I md and bd neurons with NP2225-Gal4 increases muscle size and fully
rescuesmotor rhythm and NMJ eEPSP amplitude but does not rescue locomotion. In contrast, restoration of SMNwith 1003.3-Gal4 or ppk-Gal4 does not rescue
any smn mutant phenotype.
Data are represented as mean ±SEM; *p < 0.05, **p < 0.01, and ***p < 0.001. Significance was calculated versus controls except where otherwise indicated.by using a second independent motor-neuron-specific driver,
OK6-Gal4 (Figures 3E–3H). Therefore, similar to the requirement
for SMN in muscle growth, the aberrant neurotransmitter release
at the NMJ of smn mutants is not the result of the cell-autono-
mous loss of SMN in motor neurons. This result prompted us
to investigate whether SMN was required in other neuron types
in the Drosophila motor circuit.
Inhibitory inputs are important regulators of motor circuit
function (Featherstone et al., 2000), so we next used glutamic
acid decarboxylase 1 promoter Gal4 to restore SMN in
GABAergic neurons; however, we observed no significant
rescue of any smn mutant phenotype (Figures 3E–3H). The
majority of excitatory neurons in the Drosophila nervous system
are cholinergic (Salvaterra and Kitamoto, 2001), and motor
neurons receive synaptic input from cholinergic neurons (Baines,
2006). We therefore restored transgenic SMN in smnmutants by
using choline acetyltransferase (Cha) promoter-driven Gal4. In
contrast to glutamatergic and GABAergic drivers, expression
of transgenic SMN in cholinergic neurons completely rescued
the muscle growth, locomotion, and rhythmic activity defects432 Cell 151, 427–439, October 12, 2012 ª2012 Elsevier Inc.of smn mutants (Figures 3E–3G). Moreover, expression of SMN
in cholinergic neurons also fully rescued eEPSP amplitudes at
the NMJ terminals of smn mutants to control levels (Figures 3D
and 3H). Thus, expression of SMN only in cholinergic neurons
is sufficient to fully rescue smn mutant phenotypes and can
nonautonomously rescue the SMN-dependent defects of both
motor neurons and muscles.
SMN Is Required in Both Proprioceptive and Central
Cholinergic Neurons
All Drosophila larval sensory neurons, in addition to the majority
of excitatory central neurons, are cholinergic (Salvaterra and Ki-
tamoto, 2001). To dissect the requirement for normal SMN levels
between these two populations, we examined the ability of
transgenic SMN expression in sensory neurons alone to rescue
smn mutant phenotypes. Drosophila sensory neurons are cate-
gorized into three major types: multiple dendrite neurons (md),
of which there are five subclasses (bd, I, II, III, and IV); external
sense organ neurons (es); and chordotonal neurons (ch). We first
used a panel of sensory neuron Gal4 drivers (Figure 4A) to
restore SMN only in major types of sensory neurons. We found
that when we reinstituted SMN in all md neurons and es sensory
neurons, but not ch neurons or central neurons, both the
rhythmic motor output and evoked NMJ eEPSP amplitudes of
smnmutants were restored to control levels, andmuscle surface
area was increased to 83.5% of controls (p < 0.05) (Figures 4D,
4F, and 4G). However, expression of transgenic SMN with this
driver did not significantly change the locomotion of smn
mutants (Figure 4E). In contrast, expression of SMN in ch
neurons did not rescue any smn mutant phenotype (Figures
4D–4G). Using additional Gal4 drivers that are expressed in
smaller subsets of md or es sensory neurons (Figure 4A), we
found that it was sufficient to restore SMN only in bd and type
I md neurons to rescue defects of rhythmic motor output
and NMJ neurotransmission and to increase the muscle growth
of smn mutants (Figures 4D, 4F, and 4G). Expression of SMN in
both the CNS and peripheral cholinergic neurons with Cha-Gal4
fully rescues all phenotypes, including locomotion and muscle
size (Figures 4D–4G). This suggests that, in addition to bd and
type I md sensory neurons, SMN must be restored in at least
one other additional population of cholinergic neurons that
resides within the CNS to completely correct smn mutant loco-
motion and to fully restore muscle size.
Both bd and type I md sensory neurons are required for pro-
prioceptive feedback to the motor circuit of Drosophila larvae
(Cheng et al., 2010; Hughes and Thomas, 2007). To determine
whether these neurons were morphologically disrupted by
SMN depletion, we examined the sensory or axonal processes
of the bd and type I md neurons labeled in smn mutants;
however, we found no obvious defects in sensory processes
(data not shown), and the axons of these neurons projected
into the CNS similarly to controls (Figures 4B and 4C). Our
data therefore suggested that reduced SMN in proprioceptive
neurons might disrupt their function rather than their develop-
ment or connectivity.
smnMutant Phenotypes Can Be Rescued after
Embryogenesis
Drosophila larval neurons develop, connect, and become
functional during the 21 hr of embryonic development prior to
hatching (Baines, 2006). To determine whether SMN depletion
could have disrupted nervous system assembly during this
period, we used the ‘‘GeneSwitch’’ RU486-drug-inducible
Gal4 system to control the temporal restoration of transgenic
SMN. We first asked whether smn mutant phenotypes could
be rescued by expression of transgenic SMN subsequent to
the completion of embryogenesis by exposing smn mutant
larvae and controls carrying the neuron-specific elav-GeneS-
witch driver to RU486-containing media immediately after
hatching and throughout the subsequent larval period (Fig-
ure 5A). When transgenic SMN expression was not induced,
we found no difference compared to smn mutants alone
(Figures 5C–5F). In contrast, when SMN expression was induced
immediately after embryogenesis, third instar larval muscle size,
locomotion, rhythmic motor output, and motor neuron eEPSP
amplitudes were indistinguishable from control animals (Figures
5B–5F). This result established that restoration of SMN expres-
sion after embryogenesis can rescue smn mutants, suggestingthat they do not have persistent defects in motor circuit
assembly.
We next delayed SMN expression in the nervous system of
smn mutants until progressively later larval stages. When we
induced transgenic SMN in smn mutants at 48 or 96 hr after
embryo hatching, we found intermediate phenotypes where
muscle volume, motor rhythm defects, and locomotion were
only partially restored compared to controls (Figures 5C and
5D). In contrast, NMJ eEPSP amplitudes were completely
restored in smn mutants to control levels by only 48 hr of SMN
expression (Figures 5B and 5F). These results revealed a differ-
ential phenotypic sensitivity to the timing of SMN restoration
with NMJ neurotransmitter fully corrected by elevating SMN
levels at even late stages, whereas locomotion, motor rhythm,
and muscle growth required an earlier or longer duration of
exposure to increased SMN levels.
Inhibiting Cholinergic Neuron Activity Mimics Aspects
of SMN Depletion
DuringDrosophila embryonic development, complete removal of
cholinergic input onto motor neurons results in motor neuron
hyperexcitability and increased neurotransmission (Baines
et al., 2001). We hypothesized, therefore, that the nonautono-
mous changes of motor neuron properties in smnmutants might
be explained by defective excitatory input from cholinergic
neurons in the motor circuit. Complete loss or inhibition of all
cholinergic neuron activity results in embryonic lethality (Kita-
moto et al., 2000), so in order to test this hypothesis, we
employed transgenes designed to partially inhibit neurotrans-
mission in cholinergic neurons. We used lines that either express
moderate levels of the human inward-rectifying channel Kir2.1,
which inhibits membrane depolarization (Paradis et al., 2001),
or express membrane-tethered Plectreurys Toxin II (PLTXII),
which inhibits synaptic N-type voltage-gated calcium channels
(Wu et al., 2008). To determine the effectiveness of this
approach, we first expressed these transgenes in motor neurons
alone using OK6-Gal4. We found that Kir2.1 reduced eEPSP
amplitudes by 32% (p < 0.001), whereas expression of PLTXII
reduced eEPSP amplitudes by 96% (p < 0.001), indicating
that both transgenes were capable of partially inhibiting
neurotransmission.
To examine the effects on the motor system of inhibiting
cholinergic neuron function, we then expressed each of these
Kir2.1 or PLTXII in the cholinergic neurons of wild-type animals
using Cha-Gal4. Expression of either transgene in cholinergic
neurons had no effect on muscle surface area (Figure 6C);
however, expression of these transgenes significantly inhibited
locomotion by 41% (p < 0.001) and 42% (p < 0.001), respectively
(Figure 6D). They also disrupted spontaneous rhythmic motor
activity, inducing a 54% (p < 0.05) or 59% (p < 0.05) increase
in average interspike intervals (Figures 6B and 6E). Importantly,
inhibition of cholinergic neuron function also resulted in
increased eEPSP amplitudes at the NMJs of glutamatergic
motor neurons (Figures 6A and 6F). Expression of Kir2.1 in
cholinergic neurons produced a 50% increase (p < 0.001) in
NMJ eEPSP amplitudes, whereas expression of PLTXII induced
a 45% increase (p < 0.001) (Figure 6F). Therefore, inhibition of
cholinergic neuron activity replicated a number of the featuresCell 151, 427–439, October 12, 2012 ª2012 Elsevier Inc. 433
Figure 5. Restoration of SMN after Embryo-
genesis Rescues smn Mutants
(A) Schematic of transgenic SMN induction in the
nervous system. RU486 is required for the acti-
vation of transgene induction by geneswitch Gal4.
Elav::geneswitch/UAS::flagSMN; smnX7/smnX7
larva were transferred to either vehicle media or
RU486-containing media immediately, 48 hr, or
96 hr after hatching.
(B) Representative traces recorded from smn
mutants that were cultured on either vehicle media
or RU486 media 0, 48, or 96 hr after hatching.
Induction of SMN at each time point fully restored
normal eEPSP amplitude.
(C–F) Quantification of muscle surface area (C),
locomotion (D), motor rhythm (E), and NMJ eEPSP
amplitude (F) normalized to controls. Muscle size,
locomotion, and motor rhythm are fully rescued if
transgenic SMN is induced immediately after
hatching, but if SMN induction is delayed, rescue
is incomplete. Induction of SMN for only 48 hr is,
however, sufficient to completely restore normal
NMJ eEPSP amplitude.
Data are represented as mean ±SEM; *p < 0.05,
**p < 0.01, and ***p < 0.001. Significance was
calculated versus controls except where other-
wise indicated.of smn mutants, including non-cell-autonomous effects on the
neurotransmitter release properties of motor neurons, which is
consistent with cholinergic neurons in the motor circuit having
reduced function in smn mutants.
Increasing Neuronal Excitability Rescues smnMutant
Phenotypes
Building upon the hypothesis that motor circuits have functional
deficits in smn mutants, we next asked whether increasing the
excitability of cholinergic neurons in these animals could
increase motor network activity and alter smn mutant pheno-
types. Inhibition of the Shaker (Sh) type IA K
+ current by a
dominant negative (SDN) transgene enhances membrane
excitability and increases both the amplitude and duration of
eEPSPs at synaptic terminals (Mosca et al., 2005). We ex-
pressed the SDN transgene in the cholinergic neurons of smn
mutants and examined the effect upon mutant phenotypes434 Cell 151, 427–439, October 12, 2012 ª2012 Elsevier Inc.(Figures 7A–7G). Expression of SDN
completely restored the muscle surface
area, locomotor velocity, rhythmic motor
activity, and eEPSP amplitudes of smn
mutants to levels indistinguishable from
control animals (Figures 7D–7G). This
striking result established that increasing
the activity of cholinergic neurons in the
motor circuit of smn mutants can result
in robust phenotypic rescue.
As genetic methods to inhibit K+
channel activity benefited smn mutant
phenotypes, we next asked whether
pharmacological antagonists of K+channels could also be effective. 4-aminopyridine (4-AP) is an
FDA-approved small-molecule inhibitor of voltage-activated
vertebrate (Hayes, 2007) and Drosophila K+ channels (Wicher
et al., 2001). We added 4-AP to larval media and titrated the
compound to identify the maximum dosage at which the drug
could be tolerated without lethality in wild-type larvae (2 mM).
We then examined the effects of exposure of 4-AP throughout
the larval period in both control and smn mutants. In control
animals, 4-AP had no effect on muscle size but reduced larval
locomotion by 35% (p < 0.01), decreased rhythmicmotor activity
by 40% (p < 0.01), and reduced NMJ eEPSP amplitudes by 21%
(p < 0.001), indicating mild systemic toxicity at this dose (Figures
7D–7G). Despite this, when we grew smn mutants on 4-AP-
containing media throughout the larval period, muscle surface
area was increased by 66% (p < 0.001) compared to untreated
smn mutants (Figure 7D). Locomotion was also increased by
55% (p < 0.05) and was not significantly different to controls
Figure 6. Inhibiting Cholinergic Neuron Activity Mimics smnMutant
Phenotypes
(A) Representative traces recorded from the NMJ of control or UAS-human
Kir2.1 or UAS-PLTXII expressed in cholinergic neurons with Cha-Gal4.
Inhibiting cholinergic neuron excitability with Kir2.1 or neurotransmitter release
with PLTXII increases motor neuron NMJ eEPSP amplitude.
(B) Expression of Kir2.1 or PLTX in cholinergic neurons disrupts rhythmic
motor activity.
(C–F) Quantification of muscle surface area (C), locomotion (D), motor rhythm
(E), and NMJ eEPSP amplitude (F) normalized to controls. Expression of Kir2.1
or PLTXII in cholinergic neurons does not alter muscle size but does reduce
locomotor speed, disruptmotor rhythm, and increases NMJ eEPSP amplitude.
Data are represented as mean ±SEM; *p < 0.05 and ***p < 0.001.treated with 4-AP (Figure 7E). Defects in rhythmic motor activity
in smn mutants were substantially improved, with the aberrant
increase in interspike interval reduced to 31% (p < 0.001) above
controls treatedwith 4-AP (Figure 7F). Finally, the increasedNMJ
EPSP amplitude of smnmutants treated with 4-AP was reduced
by 27% (p < 0.001), which is not significantly different than that
of 4-AP-treated controls (Figure 7G). Thus, pharmacological
inhibition of K+ channels, similar to genetic inhibition, can benefit
smn mutant phenotypes, which is consistent with the defectiveexcitability of motor circuits being a critical consequence of
SMN depletion.
DISCUSSION
Across organisms, the function of the motor system seems
uniquely sensitive to low levels of the ubiquitous protein SMN,
the molecular defect responsible for SMA (Burghes and Beattie,
2009; Schmid and DiDonato, 2007). This is also true in
Drosophila, in which smn mutants have reduced muscle size
and locomotion, which we find is accompanied by defects in
rhythmic motor output and motor neuron neurotransmitter
release. Surprisingly, restoration of SMN in the motor neurons
or muscles of these mutants provided no phenotypic rescue.
Instead, SMNmust be reinstated in both cholinergic propriocep-
tive and central neurons to rescue smn mutant phenotypes,
including non-cell-autonomous defects in both motor neurons
and muscles. Proprioceptive neurons provide essential inputs
to motor circuits (Hughes and Thomas, 2007), and cholinergic
interneurons are critical for Drosophila CNS function (Kitamoto
et al., 2000), including synaptic output onto motor neurons
(Baines et al., 2001). Restoration of SMN after the completion
of nervous system development is sufficient to rescue SMN-
dependent phenotypes, arguing that it is not the connectivity
but rather the function of motor circuits that is disrupted by
depletion of SMN. Two lines of evidence further support this
conclusion. First, inhibiting the activity of cholinergic neurons
can mimic a number of smn mutant phenotypes, including
nonautonomous effects on motor neurons. Second, increasing
the excitability of motor circuits through K+ channel inhibition
can rescue smn mutant defects. Our results therefore demon-
strate that depletion of SMN in Drosophila causes the dysfunc-
tion of a select subset of neurons in the motor circuit, which
consequently disrupts the activity of other networked compo-
nents of the motor system such as motor neurons and muscles.
These findings establish this model of SMA as a paradigm for
a neurological disease induced by neuronal circuit dysfunction.
The Contribution of Cholinergic Neurons to Drosophila
Motor Circuits
Although our results exclude a cell-autonomous requirement for
normal SMN levels in Drosophila motor neurons to rescue smn
mutants, our data do establish that SMN has to be restored in
at least two groups of motor circuit neurons for full rescue of
larval phenotypes. One of these groups is bd and type I md
sensory neurons, which are essential components of a proprio-
ceptive sensory feedback circuit necessary for coordinated
contractile locomotion of Drosophila larvae (Hughes and
Thomas, 2007). Both bd and type I md subsets of sensory
neurons express the mechanosensitive NompC transcript
receptor potential (TRP) channel, which is essential for proprio-
ception (Cheng et al., 2010). Sensory feedback does not seem
to be necessary for Drosophila larval central pattern generator
assembly or basic embryonic and larval movement (Crisp
et al., 2008); however, without sensory input, both rhythmic
motor circuit activity (Fox et al., 2006) and coordinated locomo-
tion behavior are severely disrupted (Hughes and Thomas, 2007;
Song et al., 2007). Rescue of SMN in bd and type I md sensoryCell 151, 427–439, October 12, 2012 ª2012 Elsevier Inc. 435
Figure 7. Genetic or Pharmacological Inhi-
bition of K+ Channels Ameliorates smn
Mutant Phenotypes
(A–C) Locomotion path traces from control (A),
smn mutants (B), and smn mutants expressing
a UAS dominant negative Shaker K+ channel
(UAS-SDN) in cholinergic neurons with Cha-Gal4
(C). Expressing SDN rescues the locomotion of
smn mutants.
(D–G) Quantification of muscle surface area (D),
locomotion (E), motor rhythm (F), and NMJ eEPSP
amplitude (G) normalized to controls. Expression
of SDN in cholinergic neurons with Cha-Gal4
restores muscle size (D), locomotion (E), motor
rhythm (F), and NMJ eEPSP (G) of smnmutants to
control levels. Addition of 2 mM 4-AP to culture
media throughout larval development does not
alter muscle size in control animals but increases
the muscle size of smn mutants (D). 4-AP admin-
istration inhibits locomotion, motor rhythm, and
eEPSP size in control animals. Administration of
4-AP to smn mutants corrects locomotion (E) and
NMJ eEPSP (G) to levels not significantly different
from control 4-AP-treated animals and substan-
tially corrects defects in motor rhythm (F).
Data are represented as mean ±SEM; *p < 0.05,
**p < 0.01, and ***p < 0.001. Significance was
calculated versus controls except where other-
wise indicated.neurons can restore the rhythmic motor output of smn mutants,
which is consistent with an important role for sensory input in
regulating this activity (Fox et al., 2006). However, restoration
of SMN in proprioceptive neurons alone is not sufficient to
correct the locomotion velocity of smn mutants, indicating that
additional neurons require wild-type levels of SMN in order to
restore full mobility.
SMN expression in all cholinergic neurons can completely
rescue all smn mutant larval phenotypes, including locomotion.
Our results therefore implicate an additional cell-autonomous
requirement for SMN in one or more groups of central cholin-
ergic neurons. Establishing the identity of these central neurons
will be a challenge, given our limited understanding of central
motor circuitry in Drosophila. It is tempting to speculate that
these neurons could be descending inputs from the brain
(Cattaert and Birman, 2001) or other connections between
segmental central pattern generators that promote the coordi-
nation necessary for effective locomotion. However, although
rescue analysis demonstrates that individual components of436 Cell 151, 427–439, October 12, 2012 ª2012 Elsevier Inc.the motor circuit can make significant
contributions to some smn mutant
phenotypes, other phenotypes such as
muscle growth additively require SMN in
both central and peripheral cholinergic
neurons. Therefore, our data suggest
that the effect of SMN depletion on the
motor network is an amalgam of specific
defects in distinct neurons that sum to
produce a generalized disruption of the
motor system.Why are cholinergic motor circuit neurons selectively suscep-
tible to SMN depletion? In a companion manuscript (Lotti et al.,
2012), we describe a sequence of molecular events that link
reduction of SMN to selective motor circuit dysfunction. We
show that loss of Drosophila SMN disrupts minor splicing, which
is required for the expression of genes with rare U12-type introns
(Patel and Steitz, 2003). Through a genome-wide analysis of
Drosophila U12 intron-containing genes, we identified a trans-
membrane protein, Stasimon, that has both reduced expression
in smn mutants and increased NMJ eEPSP amplitudes when
mutated, which is similar to the smn mutant phenotype. We
found that, like SMN, Stasimon is required in cholinergic
neurons, but not in motor neurons, to affect NMJ electrophysi-
ology. Furthermore, we demonstrate that transgenic expres-
sion of Stasimon can fully restore normal NMJ eEPSP ampli-
tudes in smn mutants in addition to increasing muscle size.
These data establish that reduction of SMN decreases expres-
sion of a subset of genes that are particularly sensitive to
SMN-dependent splicing disruption. Some of these genes,
such as stasimon, are critically required for the normal function of
cholinergic motor circuit neurons in Drosophila. These results
establish a mechanistic chain linking the role of SMN in RNA
splicing to the selective vulnerability of motor circuit function
when SMN is depleted.
Parallels between Drosophila and Mammalian Motor
Circuits
Although the basic elements of motor circuits—proprioceptive
neurons, interneurons, and motor neurons—are conserved
between Drosophila and humans, the neuronal constituents
and connections that make up Drosophila central motor circuitry
are at present unknown, limiting comparisons with mammalian
circuits. However, it is known that the neurotransmitters em-
ployed in each system are different (Marder and Rehm, 2005).
For example, human and mouse motor neurons are cholinergic,
whereas proprioceptive neurons are glutamatergic, the inverse
of the neurotransmitters employed in Drosophila motor circuits.
Therefore, one possible interpretation of our results is that
cholinergic neurons have a particular and conserved sensitivity
to the reduced levels of SMN. Neurotransmitter release is
defective from the cholinergic motor neurons of SMN-D7 mice
(Kong et al., 2009; Park et al., 2010a), and this defect does
appear to require the cell-autonomous presence of normal
SMN levels in these neurons (Park et al., 2010b). Nonetheless,
SMN-D7 mutants have normal muscle twitch tension (Ling
et al., 2010), targeted depletion of SMN in motor neurons does
not cause lethality (Park et al., 2010b), and selective restoration
of SMN in motor neurons alone or cholinergic neurons alone
produces only a few days of survival benefit to mutant animals
(Gogliotti et al., 2012; Martinez et al., 2012). These results imply
that, if indeed cholinergic neurons are selectively affected by
reduction of SMN, additional neurons in the mammalian motor
circuit must also be involved.
An alternative, though not necessarily exclusive, interpreta-
tion is that conserved network elements of motor circuits are
vulnerable to low levels of SMN. In support of this, it has
recently been shown that SMN-D7 mice have early reduced
responses to afferent fiber activation (Mentis et al., 2011), which
are accompanied by a later decrease in glutamatergic proprio-
ceptive synapses from sensory afferents onto motor neurons
(Ling et al., 2010; Mentis et al., 2011). SMA patients have also
been reported to have reduced or absent H-reflexes (Renault
et al., 1983), which could be consistent with decreased activity
of motor reflex circuits. Interestingly, in a companion manu-
script (Lotti et al., 2012), we show that the splicing and expres-
sion of the SMN-dependent gene Stasimon is preferentially
disrupted in the proprioceptive neurons of SMN-D7 motor
circuits, though motor neurons are also affected. The concor-
dant evidence for defective sensory-motor function in both
mammalian and Drosophila SMN mutants is striking but also
unexpected, even with our limited understanding of the central
circuitry of both systems. For example, both mouse and human
motor neurons receive direct synaptic input onto both somata
and dendrites from sensory afferents (Chen et al., 2003),
whereas Drosophila motor neuron dendrites do not appear
to contact proprioceptive axon processes (Zlatic et al.,
2009). Restoration of SMN in the proprioceptive neurons ofDrosophila smn mutants is sufficient to restore normal NMJ
neurotransmitter release properties in motor neurons. This
suggests that, even without direct synaptic contact, increasing
SMN in these neurons can influence motor neuron electrophys-
iological properties, presumably through intermediate inter-
neuron connections. Therefore, it is possible that, although
the specific details of motor circuit wiring differ between
Drosophila and vertebrates, the essential relationships and
function of motor networks are conserved and selectively
susceptible to depletion of SMN.
Manipulating Motor Circuit Excitability in smn Mutants
Drosophila smn mutants have increased NMJ eEPSP amplitude
and mEPSP frequency, which is consistent with an increased
excitability of motor neurons. Hyperexcitability of motor neurons
has also been described in the SMA-D7 mouse model (Mentis
et al., 2011). In Drosophila, this increase in neurotransmitter
release properties is not corrected by restoring SMN in motor
neurons themselves but is rescued by expressing SMN in cholin-
ergic neurons. Hyperexcitability of Drosophila motor neurons
has previously been reported in embryos in which cholinergic
neurotransmission is completely inhibited (Baines et al., 2001).
Congruent with this, we could replicate the increased evoked
neurotransmitter release from smn mutant motor neurons by
inhibiting cholinergic neurotransmission in larvae, which is
consistent with a homeostatic compensatory increase in the
excitability of motor neurons when synaptic inputs are reduced.
A similar phenomenon has recently been described in chicken
magnocellular neurons, which, when deafferentated by removal
of the cochlea, increase in excitability (Kuba et al., 2010).
Increasing neuronal excitability by inhibiting K+ channels in
smn mutants gave a remarkably robust rescue of muscle size,
locomotion, rhythmic motor output, and NMJ neurotransmis-
sion. The Shaker type IA K
+ current plays a critical role in the
regulation of membrane excitability in Drosophila neurons, and
expression of a dominant negative construct inhibiting the Sh
current (Mosca et al., 2005) in cholinergic neurons of smn
mutants fully rescues all the larval phenotypes we examined.
Together, these results strongly argue that decreased excit-
ability of motor circuit neurons is a key physiological outcome
of reduced levels of SMN.
Treatment with the small-molecule K+ channel antagonist 4-
AP also showed benefit to Drosophila smn mutant phenotypes.
In wild-type animals, 4-AP treatment did not affect muscle size
but did reduce locomotion and inhibited NMJ neurotransmitter
release as might be anticipated by systemic inhibition of K+
channels, which are present throughout the nervous system
and in muscles (Wicher et al., 2001). Nonetheless, administration
of 4-AP significantly increased both the muscle area and loco-
motion of smn mutants and fully corrected defects in rhythmic
motor output and NMJ neurotransmission. Treatment with
4-AP has been linked to functional improvement of patients
with spinal cord injury, myasthenia gravis, and Lambert-Eaton
syndrome (Hayes, 2007) and can improve muscle twitch tension
in a canine hereditary motor neuron disease (Pinter et al., 1997).
A sustained release preparation of 4-AP was recently approved
by the FDA for human clinical use inmultiple sclerosis (Chwieduk
and Keating, 2010). Our data suggest that the efficacy of 4-AP inCell 151, 427–439, October 12, 2012 ª2012 Elsevier Inc. 437
the Drosophila smn mutant model is likely via its activity upon
cholinergic neurotransmission in the sensory-motor circuit.
Extrapolating this finding to humans, investigation of com-
pounds like 4-AP that can act within the spinal cord to modify
the excitability of motor neural networks could be a fruitful
therapeutic strategy to ameliorate the symptoms of SMA.
EXPERIMENTAL PROCEDURES
Drosophila Stocks
The mutants smnX7 (Chang et al., 2008), smn73Ao (Chan et al., 2003), smnE33
(Rajendra et al., 2007) were utilized. Gal4 and UAS lines are described in
Supplemental Information.
Muscle Measurement
Muscle area measurements were carried out at muscle 6, segment A3 of
phalloidin-stained muscle fillet preparations (Brent et al., 2009).
Locomotion
Larval locomotion assays were essentially performed as previously described
(Suster and Bate, 2002).
Motor Rhythm
Spontaneous motor rhythm was recorded as previously described (Fox et al.,
2006). To measure the average interspike interval, the peak detection feature
of MiniAnalysis (Synaptosoft, Inc.) was used to detect all spontaneous eEPSPs
events that occurred during a 3 min period.
NMJ Electrophysiology
Intracellular recordings from muscle 6, segment A3 were performed as
previously described (Imlach and McCabe, 2009).
Drug Treatment
Gene-switch GAL4 SMN expression was induced by culturing larvae with
RU486 at 10 mg/ml for 148, 96, 72, or 48 hr prior to phenotypic measurement
in smn mutants (controls were all assayed at wandering L3 stage). SMN
induction was confirmed by western blot. For 4-AP treatment, 2 mM 4-AP
(Sigma) was added to the yeast paste on which larvae were cultured immedi-
ately after hatching and throughout the subsequent larval period.
Statistical Methods
Significance was tested by analysis of variance (ANOVA).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, two
figures, and one table and can be found with this article online at http://dx.
doi.org/10.1016/j.cell.2012.09.011.
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